Global Respiratory Syncytial Virus (RSV) Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Respiratory Syncytial Virus (RSV) Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Respiratory Syncytial Virus (RSV) Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Respiratory Syncytial Virus (RSV) Therapeutics market is projected to reach US$ 837.5 million in 2034, increasing from US$ 564.7 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2034. Demand from Hospital Pharmacies and Drug Stores are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Respiratory Syncytial Virus (RSV) Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Respiratory Syncytial Virus (RSV) Therapeutics key companies include Roche, AstraZeneca, Merck, AbbVie, Bausch Health, GlaxoSmithKline, ReViral, Gilead Sciences and Teva Pharmaceutical, etc. Roche, AstraZeneca, Merck are top 3 players and held % share in total in 2022.
Respiratory Syncytial Virus (RSV) Therapeutics can be divided into Palivizumab, Ribavirin and Others,, etc. Palivizumab is the mainstream product in the market, accounting for % share globally in 2022.
Respiratory Syncytial Virus (RSV) Therapeutics is widely used in various fields, such as Hospital Pharmacies, Drug Stores, Retail Pharmacies and Others, etc. Hospital Pharmacies provides greatest supports to the Respiratory Syncytial Virus (RSV) Therapeutics industry development. In 2022, global % share of Respiratory Syncytial Virus (RSV) Therapeutics went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Respiratory Syncytial Virus (RSV) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Sale Channel and Regions Listed in the Report
Roche
AstraZeneca
Merck
AbbVie
Bausch Health
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical
Segment by Type
Palivizumab
Ribavirin
Others
Segment by Sale Channel
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Respiratory Syncytial Virus (RSV) Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Sale Channel and Revenue analysis of Each Sale Channel in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Respiratory Syncytial Virus (RSV) Therapeutics introduction, etc. Respiratory Syncytial Virus (RSV) Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Respiratory Syncytial Virus (RSV) Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Respiratory Syncytial Virus (RSV) Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Respiratory Syncytial Virus (RSV) Therapeutics key companies include Roche, AstraZeneca, Merck, AbbVie, Bausch Health, GlaxoSmithKline, ReViral, Gilead Sciences and Teva Pharmaceutical, etc. Roche, AstraZeneca, Merck are top 3 players and held % share in total in 2022.
Respiratory Syncytial Virus (RSV) Therapeutics can be divided into Palivizumab, Ribavirin and Others,, etc. Palivizumab is the mainstream product in the market, accounting for % share globally in 2022.
Respiratory Syncytial Virus (RSV) Therapeutics is widely used in various fields, such as Hospital Pharmacies, Drug Stores, Retail Pharmacies and Others, etc. Hospital Pharmacies provides greatest supports to the Respiratory Syncytial Virus (RSV) Therapeutics industry development. In 2022, global % share of Respiratory Syncytial Virus (RSV) Therapeutics went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Respiratory Syncytial Virus (RSV) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Sale Channel and Regions Listed in the Report
By Company
Roche
AstraZeneca
Merck
AbbVie
Bausch Health
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical
Segment by Type
Palivizumab
Ribavirin
Others
Segment by Sale Channel
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Respiratory Syncytial Virus (RSV) Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Sale Channel and Revenue analysis of Each Sale Channel in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Respiratory Syncytial Virus (RSV) Therapeutics introduction, etc. Respiratory Syncytial Virus (RSV) Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Respiratory Syncytial Virus (RSV) Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices